The effect of carcinogens on the accumulation of tyrosine aminotransferase by foetal rat hepatocytes in culture

George Yeoh, Machell Godfrey, Robert Toia, Maxwell Cake

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The hepatocarcinogen 3′-methyl-4-dimethyl-aminoazobenzene (MDAB) suppresses the accumulation of tyrosine aminotransferase in cultured foetal hepatocytes. Experiments involving liver derived from foetuses of various ages reveals that a response is only obtained with rats older than 16-day gestation. It has been proposed that the lack of an effect in less mature hepatocytes is due to their inability to activate the carcinogen. Chemically synthesized analogues of MDAB which are considered likely to be activated forms of the procarcinogen are shown to be effective in the less mature cells. This supports the proposal that these cells may be unreponsive because they are unable to activate MDAB. Tests with other carcinogens reveal that the hepatocarcinogen dimethylbenzanthracene is also effective in 19-day gestation hepatocytes. However, the non-hepatocarcinogens azaserine and benz(a)pyrene are ineffective. Treatment with MDAB is shown not to alter the level of steroid receptor and reduce its translocation into the nucleus, suggesting that this is not the mechanism by which TAT is suppressed. The effect of the tumour promoter phorbol-myristate acetate (PMA) administered together with MDAB was shown not to modify the response to the carcinogen alone.

Original languageEnglish
Pages (from-to)1163-1170
Number of pages8
JournalEuropean Journal of Cancer and Clinical Oncology
Volume18
Issue number11
DOIs
Publication statusPublished - 1 Jan 1982

Fingerprint

Tyrosine Transaminase
Carcinogens
Hepatocytes
Azaserine
Pregnancy
Steroid Receptors
Tetradecanoylphorbol Acetate
Fetus
Liver

Cite this

@article{87268e9850094690b0e377c948527b71,
title = "The effect of carcinogens on the accumulation of tyrosine aminotransferase by foetal rat hepatocytes in culture",
abstract = "The hepatocarcinogen 3′-methyl-4-dimethyl-aminoazobenzene (MDAB) suppresses the accumulation of tyrosine aminotransferase in cultured foetal hepatocytes. Experiments involving liver derived from foetuses of various ages reveals that a response is only obtained with rats older than 16-day gestation. It has been proposed that the lack of an effect in less mature hepatocytes is due to their inability to activate the carcinogen. Chemically synthesized analogues of MDAB which are considered likely to be activated forms of the procarcinogen are shown to be effective in the less mature cells. This supports the proposal that these cells may be unreponsive because they are unable to activate MDAB. Tests with other carcinogens reveal that the hepatocarcinogen dimethylbenzanthracene is also effective in 19-day gestation hepatocytes. However, the non-hepatocarcinogens azaserine and benz(a)pyrene are ineffective. Treatment with MDAB is shown not to alter the level of steroid receptor and reduce its translocation into the nucleus, suggesting that this is not the mechanism by which TAT is suppressed. The effect of the tumour promoter phorbol-myristate acetate (PMA) administered together with MDAB was shown not to modify the response to the carcinogen alone.",
author = "George Yeoh and Machell Godfrey and Robert Toia and Maxwell Cake",
year = "1982",
month = "1",
day = "1",
doi = "10.1016/0277-5379(82)90098-0",
language = "English",
volume = "18",
pages = "1163--1170",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon",
number = "11",

}

The effect of carcinogens on the accumulation of tyrosine aminotransferase by foetal rat hepatocytes in culture. / Yeoh, George; Godfrey, Machell; Toia, Robert; Cake, Maxwell.

In: European Journal of Cancer and Clinical Oncology, Vol. 18, No. 11, 01.01.1982, p. 1163-1170.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of carcinogens on the accumulation of tyrosine aminotransferase by foetal rat hepatocytes in culture

AU - Yeoh, George

AU - Godfrey, Machell

AU - Toia, Robert

AU - Cake, Maxwell

PY - 1982/1/1

Y1 - 1982/1/1

N2 - The hepatocarcinogen 3′-methyl-4-dimethyl-aminoazobenzene (MDAB) suppresses the accumulation of tyrosine aminotransferase in cultured foetal hepatocytes. Experiments involving liver derived from foetuses of various ages reveals that a response is only obtained with rats older than 16-day gestation. It has been proposed that the lack of an effect in less mature hepatocytes is due to their inability to activate the carcinogen. Chemically synthesized analogues of MDAB which are considered likely to be activated forms of the procarcinogen are shown to be effective in the less mature cells. This supports the proposal that these cells may be unreponsive because they are unable to activate MDAB. Tests with other carcinogens reveal that the hepatocarcinogen dimethylbenzanthracene is also effective in 19-day gestation hepatocytes. However, the non-hepatocarcinogens azaserine and benz(a)pyrene are ineffective. Treatment with MDAB is shown not to alter the level of steroid receptor and reduce its translocation into the nucleus, suggesting that this is not the mechanism by which TAT is suppressed. The effect of the tumour promoter phorbol-myristate acetate (PMA) administered together with MDAB was shown not to modify the response to the carcinogen alone.

AB - The hepatocarcinogen 3′-methyl-4-dimethyl-aminoazobenzene (MDAB) suppresses the accumulation of tyrosine aminotransferase in cultured foetal hepatocytes. Experiments involving liver derived from foetuses of various ages reveals that a response is only obtained with rats older than 16-day gestation. It has been proposed that the lack of an effect in less mature hepatocytes is due to their inability to activate the carcinogen. Chemically synthesized analogues of MDAB which are considered likely to be activated forms of the procarcinogen are shown to be effective in the less mature cells. This supports the proposal that these cells may be unreponsive because they are unable to activate MDAB. Tests with other carcinogens reveal that the hepatocarcinogen dimethylbenzanthracene is also effective in 19-day gestation hepatocytes. However, the non-hepatocarcinogens azaserine and benz(a)pyrene are ineffective. Treatment with MDAB is shown not to alter the level of steroid receptor and reduce its translocation into the nucleus, suggesting that this is not the mechanism by which TAT is suppressed. The effect of the tumour promoter phorbol-myristate acetate (PMA) administered together with MDAB was shown not to modify the response to the carcinogen alone.

UR - http://www.scopus.com/inward/record.url?scp=0020411040&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(82)90098-0

DO - 10.1016/0277-5379(82)90098-0

M3 - Article

VL - 18

SP - 1163

EP - 1170

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 11

ER -